Assessment-Schedule Matching in Unanchored Indirect Treatment Comparisons of Progression-Free Survival in Cancer Studies-Reference-Cited by-同舟云学术

Assessment-Schedule Matching in Unanchored Indirect Treatment Comparisons of Progression-Free Survival in Cancer Studies

Published:2019-09-26 Issue:12 Volume:37 Page:1537-1551
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Kapetanakis Venediktos^ORCID,Prawitz Thibaud,Schlichting Michael,Ishak K. Jack,Phatak Hemant,Kearney Mairead,Stevens John W.,Benedict Agnes,Bharmal Murtuza

Funder

Merck Healthcare KGaA

Pfizer

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s40273-019-00831-3.pdf

Reference16 articles.

1. Zeng L, Cook RJ, Wen L, Boruvka A. Bias in progression-free survival analysis due to intermittent assessment of progression. Stat Med. 2015;34(24):3181–93.

2. Panageas KS, Ben-Porat L, Dickler MN, Chapman PB, Schrag D. When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst. 2007;99(6):428–32.

3. Qi Y, Allen Ziegler KL, Hillman SL, et al. Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer. Cancer. 2012;118(21):5358–65.

4. Hatswell AJ, Baio G, Berlin JA, Irs A, Freemantle N. Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999–2014. BMJ Open. 2016;6(6):e011666.

5. Alexiou D, Chatzitheofilou I, Pi Blanque A. A review of NICE technology appraisals in oncology using single arm trials (SAT) evidence [abstract no. PRM85]. Value Health. 2018;21:S224.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Measurement error and bias in real-world oncology endpoints when constructing external control arms;Frontiers in Drug Safety and Regulation;2024-07-19

2. Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate Cancer;Advances in Therapy;2024-07-03

3. Long-Term Comparative Efficacy and Safety of Risdiplam and Nusinersen in Children with Type 1 Spinal Muscular Atrophy;Advances in Therapy;2024-05-05

4. Framework for the Use of External Controls to Evaluate Treatment Outcomes in Precision Oncology Trials;JCO Precision Oncology;2024-02

5. Modelling Health State Utilities as a Transformation of Time to Death in Patients with Non-Small Cell Lung Cancer;PharmacoEconomics;2023-09-14